NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Wednesday, November, 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.45. The medical device company had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The business's revenue was up 48.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 earnings per share. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for DexCom.

DexCom will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $457-457 million, compared to the consensus revenue estimate of $431.47 million.

15 analysts have issued twelve-month price targets for DexCom's stock. Their forecasts range from $125.00 to $255.00. On average, they anticipate DexCom's share price to reach $207.43 in the next twelve months. This suggests that the stock has a possible downside of 11.6%. View Analyst Price Targets for DexCom.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

Media coverage about DXCM stock has trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. DexCom earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for DexCom.

Some companies that are related to DexCom include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), Home Depot (HD), ServiceNow (NOW), Micron Technology (MU), Veeva Systems (VEEV) and Tandem Diabetes Care (TNDM).

DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Chicago Capital LLC (0.21%), Peregrine Capital Management LLC (0.10%), Patten & Patten Inc. TN (0.02%), Johanson Financial Advisors Inc. (0.01%), Janney Montgomery Scott LLC (0.01%) and Gateway Investment Advisers LLC (0.01%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Gateway Investment Advisers LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, CenturyLink Investment Management Co, Janney Montgomery Scott LLC and Weatherly Asset Management L. P.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Assenagon Asset Management S.A., HWG Holdings LP, IFM Investors Pty Ltd, Exchange Traded Concepts LLC, Zeke Capital Advisors LLC and Huntington National Bank. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $234.64.

DexCom has a market capitalization of $21.48 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]